Fig. 1
From: Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
Summary of immune checkpoint-based immunotherapies for MS/EAE. Abbreviations: Ab: Antibody; APC: Antigen presenting cell; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; FOXP3: Forkhead Box P3; IFN-γ: Interferon gamma; IL-17: Interleukin 17; LAG-3: Lymphocyte activation gene 3; MBP: Myelin basic protein; MHC II: Major histocompatibility complex class II; mTOR: Mechanistic target of rapamycin; NF-κB: Nuclear factor kappa B; PD-1: Programmed cell death protein 1; PI3K: Phosphoinositide 3-kinase PSGL-1: P-selectin glycoprotein ligand 1; STAT3: Signal transducer and activator of transcription 3; TCR: T-cell receptor; Th: T helper; TIM-3: T-cell immunoglobulin and mucin-containing protein-3; VISTA: V-domain Ig suppressor of T cell activation